1. Home
  2. FMS vs GH Comparison

FMS vs GH Comparison

Compare FMS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fresenius Medical Care AG

FMS

Fresenius Medical Care AG

HOLD

Current Price

$24.07

Market Cap

14.2B

Sector

Health Care

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$106.64

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMS
GH
Founded
1996
2011
Country
Germany
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2B
13.3B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FMS
GH
Price
$24.07
$106.64
Analyst Decision
Sell
Strong Buy
Analyst Count
2
22
Target Price
$30.00
$103.82
AVG Volume (30 Days)
617.1K
1.8M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
2.36%
N/A
EPS Growth
N/A
6.74
EPS
N/A
N/A
Revenue
N/A
$982,021,000.00
Revenue This Year
$2.15
$29.73
Revenue Next Year
$2.15
$27.71
P/E Ratio
$15.62
N/A
Revenue Growth
N/A
32.88
52 Week Low
$20.96
$34.91
52 Week High
$30.46
$120.74

Technical Indicators

Market Signals
Indicator
FMS
GH
Relative Strength Index (RSI) 56.59 49.95
Support Level $23.82 $102.00
Resistance Level $24.71 $110.46
Average True Range (ATR) 0.40 6.19
MACD 0.11 -0.33
Stochastic Oscillator 71.40 46.62

Price Performance

Historical Comparison
FMS
GH

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: